ALNYALNYLAM PHARMACEUTICALS, INC.
Health Care
Net Income (Loss) Attributable to Parent revised up 16.6% for Q3 2025
This is the 9th largest revision in ALNY's history.
Net Income (Loss) Attributable to Parent·Q3 2025
Major restatement$292.7M▲ 16.6%
was$251.1M
Revised up in a 10-Q. Any P/E built on the original was 14.2% too high.
Verify against SEC filingsShow
As reported$251.1M
Accepted 2025-10-300001628280-25-047345
Restated$292.7M
Accepted 2026-10-290001178670-26-000076
NetIncome · reported 2 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time ALNY — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.